Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286470 | 0.86 | KMT2A (0.39) | KMT2AL3MBTL1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL285698 | 0.86 | KMT2A (0.39) | KMT2AL3MBTL1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL286228 | 0.86 | ALDH1A1 (0.36) | KMT2AL3MBTL1ALDH1A1GABRA5SMN1; SMN2 | |
| SCHEMBL285759 | 0.85 | GABRA5 (0.41) | L3MBTL1GABRA5 | |
| SCHEMBL2749182 | 0.84 | GAA (0.40) | L3MBTL1ALDH1A1HTTGABRA5SMN1; SMN2 | |
| SCHEMBL286095 | 0.82 | GABRA5 (0.43) | L3MBTL1GABRA5 | |
| SCHEMBL295001 | 0.80 | GABRA5 (0.54) | GABRA5 | |
| SCHEMBL285760 | 0.80 | SLC8A1 (0.41) | L3MBTL1GABRA5 | |
| SCHEMBL286071 | 0.78 | GABRA5 (0.41) | L3MBTL1GABRA5 | |
| SCHEMBL286575 | 0.77 | GABRA1 (0.46) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427459-A1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |